文献速递妇科

SLC7A11与GPX4高共表达预测上皮性卵巢癌铂类耐药及不良预后

High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer.
PubMed 文献 · BJOG · 2022-01-01

该回顾性队列研究纳入2002年1月至2018年12月期间192例上皮性卵巢癌患者,对手术标本行SLC7A11与GPX4染色,采用Kaplan-Meier法和Cox回归分析生存。结果:SLC7A11与GPX4高共表达者铂类耐药风险比为60.46(95%CI 22.76-160.58,p<0.001),且为总生存(HR 4.44,95%CI 2.77-7.14,p<0.001)和无进展生存(HR 5.73,95%CI 3.86-8.73,p<0.001)不良的独立预后因素。

要点

  • SLC7A11与GPX4高共表达者铂类耐药风险比为60.46(95%CI 22.76-160.58,p<0.001)。
  • 高共表达为总生存不良的独立预后因素(HR 4.44,95%CI 2.77-7.14,p<0.001)。
  • 高共表达为无进展生存不良的独立预后因素(HR 5.73,95%CI 3.86-8.73,p<0.001)。

核心结论

  • 上皮性卵巢癌患者中SLC7A11与GPX4高表达与铂类耐药相关,高共表达可能是有意义的独立预后因素和铂类耐药的潜在治疗靶点。

研究设计与样本

  • 回顾性队列研究,纳入浙江大学医学院附属妇产科医院2002年1月至2018年12月期间192例符合条件的上皮性卵巢癌患者。
  • 对上皮性卵巢癌手术标本行SLC7A11与GPX4染色,采用Kaplan-Meier法和Cox回归法进行生存分析。
  • 主要终点包括无铂间期、无进展生存和总生存。

主要发现

  • SLC7A11与GPX4高共表达者铂类耐药风险比为60.46(95%CI 22.76-160.58,p<0.001)。
  • 高共表达为总生存不良的独立预后因素(p<0.001,HR 4.44,95%CI 2.77-7.14)。
  • 高共表达为无进展生存不良的独立预后因素(p<0.001,HR 5.73,95%CI 3.86-8.73)。
  • 体外实验中,铂类耐药细胞较其亲代卵巢癌细胞SLC7A11与GPX4表达均上调,siRNA抑制SLC7A11与GPX4可降低铂类耐药。

临床怎么用

  • 作者认为SLC7A11与GPX4高共表达可能是有意义的独立预后因素和铂类耐药的潜在治疗靶点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to assess the expression levels of SLC7A11 and GPX4 in relation to platinum resistance and prognosis in patients with epithelial ovarian cancer (EOC). DESIGN: A retrospective cohort study. SETTING: Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China. POPULATION OR SAMPLE: We included 192 eligible patients from hospital between January 2002 and December 2018. METHODS: We retrospectively analysed the medical records of patients with EOC. Surgical specimens of EOC were stained for SLC7A11 and GPX4. Survival analysis was performed using the Kaplan-Meier and Cox regression methods. MAIN OUTCOME MEASURES: Clinical end points include platinum-free interval (PFI), progression-free survival (PFS) and overall survival (OS). RESULTS: Patients with high co-expression levels of SLC7A11 and GPX4 had a 60-fold higher risk of platinum resistance compared with those with low co-expression (risk ratio, 60.46; 95% confidence interval [CI] 22.76-160.58; p < 0.001). Moreover, high co-expression level of SLC7A11 and GPX4 was an independent prognostic factor for poor OS (p < 0.001, hazard ratio [HR] 4.44, 95% CI, 2.77-7.14) and poor PFS (p < 0.001, HR = 5.73, 95% CI, 3.86-8.73). For in vitro experiments, SLC7A11 and GPX4 expression were both upregulated in platinum-resistant cells compared with their parental ovarian cancer cells, and siRNA-induced SLC7A11 and GPX4 inhibition decreased platinum resistance. CONCLUSIONS: High expression levels of SLC7A11 and GPX4 are associated with platinum resistance in EOC patients. High co-expression of SLC7A11 and GPX4 may be a significant independent prognostic factor and a potential therapeutic target for platinum resistance in EOC patients.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Wu X, Shen S, Qin J, et al. High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer. BJOG. 2022. PMID: 36485069. doi:10.1111/1471-0528.17327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。